Strohl M, Gonczi L, Kurt Z, Bessissow T, L Lakatos P. Quality of care in inflammatory bowel diseases: What is the best way to better outcomes? World J Gastroenterol 2018; 24(22): 2363-2372 [PMID: 29904243 DOI: 10.3748/wjg.v24.i22.2363]
Corresponding Author of This Article
Peter L Lakatos, DSc, MD, PhD, Professor, Staff Physician, Division of Gastroenterology, McGill University Health Center, 1650 Cedar Avenue, Montreal, Québec H4A 3J1, Canada. kislakpet99@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 14, 2018; 24(22): 2363-2372 Published online Jun 14, 2018. doi: 10.3748/wjg.v24.i22.2363
Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?
Matthew Strohl, Lorant Gonczi, Zsuzsanna Kurt, Talat Bessissow, Peter L Lakatos
Matthew Strohl, Talat Bessissow, Peter L Lakatos, Division of Gastroenterology, McGill University Health Center, Montreal, Québec H4A 3J1, Canada
Lorant Gonczi, Zsuzsanna Kurt, Peter L Lakatos, First Department of Medicine, Semmelweis University, Koranyi, Budapest 1083, Hungary
Author contributions: All authors contributed to writing of the manuscript and approved the final version for submission.
Conflict-of-interest statement: There are no conflicts of interest to report from any of the study’s authors.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Peter L Lakatos, DSc, MD, PhD, Professor, Staff Physician, Division of Gastroenterology, McGill University Health Center, 1650 Cedar Avenue, Montreal, Québec H4A 3J1, Canada. kislakpet99@gmail.com
Telephone: +36-1-2100278 Fax: +36-1-3130250
Received: March 22, 2018 Peer-review started: March 23, 2018 First decision: April 18, 2018 Revised: April 24, 2018 Accepted: April 24, 2018 Article in press: May 26, 2018 Published online: June 14, 2018 Processing time: 80 Days and 5.3 Hours
Core Tip
Core tip: The approach to diagnosis, follow up and management of inflammatory bowel disease (IBD) has undergone a major transformation in the past decade. Many different international quality indicators that span structure, process and outcome measures have been developed. These serve as major targets in optimizing quality of care (QoC). New developments have been designed to improve QoC including utilizing telemedicine, home biomarker testing and providing rapid access care to patients. Treating to target with proactive disease management guided by clinical history utilizing adjunctive biomarkers at the onset of IBD has been shown to improve objective outcomes. This will likely serve as the new favored treatment approach in many IBD centers across the globe.
